"Rifampin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
Descriptor ID |
D012293
|
MeSH Number(s) |
D03.633.400.811.700 D04.345.295.750.700
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rifampin".
Below are MeSH descriptors whose meaning is more specific than "Rifampin".
This graph shows the total number of publications written about "Rifampin" by people in this website by year, and whether "Rifampin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 2 | 2 |
1995 | 0 | 1 | 1 |
1996 | 1 | 1 | 2 |
1997 | 1 | 0 | 1 |
1998 | 3 | 1 | 4 |
1999 | 1 | 2 | 3 |
2001 | 1 | 0 | 1 |
2002 | 1 | 2 | 3 |
2003 | 4 | 1 | 5 |
2004 | 1 | 1 | 2 |
2005 | 1 | 1 | 2 |
2006 | 1 | 1 | 2 |
2007 | 0 | 1 | 1 |
2008 | 1 | 4 | 5 |
2009 | 2 | 2 | 4 |
2010 | 1 | 1 | 2 |
2011 | 1 | 3 | 4 |
2012 | 0 | 1 | 1 |
2013 | 2 | 0 | 2 |
2014 | 2 | 1 | 3 |
2015 | 1 | 5 | 6 |
2016 | 6 | 2 | 8 |
2017 | 3 | 3 | 6 |
2018 | 2 | 2 | 4 |
2019 | 2 | 1 | 3 |
2020 | 3 | 5 | 8 |
2021 | 0 | 3 | 3 |
2022 | 1 | 5 | 6 |
2023 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rifampin" by people in Profiles.
-
[Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)]. Pneumologie. 2024 Jan; 78(1):35-46.
-
Detection of Genes Encoding Microbial Surface Component Recognizing Adhesive Matrix Molecules in Methicillin-Resistant Staphylococcus aureus Isolated from Pyoderma Patients. Genes (Basel). 2023 03 24; 14(4).
-
Gene network interaction analysis to elucidate the antimicrobial resistance mechanisms in the Clostridiumdifficile. Microb Pathog. 2023 May; 178:106083.
-
Long-term treatment outcomes in patients with multidrug-resistant tuberculosis. Clin Microbiol Infect. 2023 Jun; 29(6):751-757.
-
Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in Germany. Eur Respir J. 2022 11; 60(5).
-
Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children. Cochrane Database Syst Rev. 2022 09 06; 9:CD013359.
-
Diagnostic performance of the AID line probe assay in the detection of Mycobacterium tuberculosis and drug resistance in Romanian patients with presumed TB. PLoS One. 2022; 17(8):e0271297.
-
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. Eur Respir J. 2022 05; 59(5).
-
Vikela Ekhaya: A Novel, Community-based, Tuberculosis Contact Management Program in a High Burden Setting. Clin Infect Dis. 2022 05 03; 74(9):1631-1638.
-
Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study. J Infect. 2022 06; 84(6):834-872.